A phase I, open-label, single-dose study to evaluate the effect of severe renal impairment on the pharmacokinetics of fenebrutinib
-
Autoimmune Disorder -
Multiple Sclerosis (MS)
For the latest version of this information please go to www.forpatients.roche.com